| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
Over half patients with renal failure suffer hyperparathyroidism(HPT). HPT leads to severe osteoporotic state. Recently, a CaR agonist, cinacalcet has been developed to suppress parathyroid gland. In contrast, aKlotho and FGF23 are both essential for regulating PTH secretion. We addressed the principle that aKlotho contributes to PTH secretion and then surveyed the inhibitory chemicals. Screening study revealed estron glucuronide and its derivatives are candidates for suppression of PTH secretion. These data would be seeds for PTH inhibitory drugs based on aKlotho structure.
|
